Chihara D, Huang EP, Finnigan SR, Cordes LM, et al. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol 2022;40:1949-1957.
PMID: 35263120